Latest Athersys (ATHX) Headlines Concise Analys
Post# of 90
Posted On: 03/12/2014 6:12:43 PM
Latest Athersys (ATHX) Headlines
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Athersys to Present at Regen Med Investor Day March 26th in New York
GlobeNewswire - Fri Mar 07, 12:15PM CST
Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys, Inc. (Nasdaq:ATHX), will present at the second annual Regen Med Investor Day on Wednesday, March 26, 2014 at 1:30 pm (Eastern Time). The conference will be held at the Metropolitan Club in New York City.
Japan's Bold Initiative in Regenerative Medicine and Who the Big Winners Might Be
ACCESSWIRE - Mon Mar 03, 9:55AM CST
Like many other regions in the world, Japan is facing a demographic problem that threatens to pose enormous challenges for their national healthcare system in the years ahead, as the elderly segment of the population expands dramatically. According to analysis by the Ministry of Health Labor and Welfare (MHLW) in Japan, the percentage of the population that is over the age of 65 is expected to nearly double in the coming years. Given that the aging segment of the population requires greater healthcare resources and that this shift will place substantial pressure on the national healthcare system in Japan, it is understandable that the trend has received considerable attention from policy makers.
Athersys to Host Fourth Quarter and Annual Financial Results Call
GlobeNewswire - Tue Feb 25, 9:24AM CST
Athersys, Inc. (Nasdaq:ATHX) will release its 2013 fourth quarter and annual financial results at approximately 4:00 PM EST on Thursday, March 13, 2014, and host a conference call shortly thereafter at 4:30 PM EST to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
Akpabio - No Apology for Supporting Jonathan [interview]
All Africa Global Media - Thu Feb 13, 4:36AM CST
The Akwa Ibom State Governor, Godswill Akpabio, after paying a courtesy call on the National Chairman of the Peoples Democratic Party, Adamu Mu'azu, pledged his support to the new authority. Chuks Okocha presents excerpts of the session
Athersys to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 9:00AM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that the Company will present at the 2014 BIO CEO & Investor Conference to be held at the Waldorf Astoria from February 10-11, 2014 in New York City.
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013 Report
M2 - Mon Feb 03, 2:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/f28drr/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013" report to their offering. 'Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). Scope - A snapshot of the global therapeutic scenario for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). - A review of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Athersys, Inc. OPKO Health, Inc. Amicus Therapeutics, Inc. ReGenX Biosciences, LLC ArmaGen Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/f2...saccharido About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Companies Aligned to Capitalize on New Japanese Regenerative Medicine Initiatives
ACCESSWIRE - Mon Jan 13, 9:09AM CST
Thanks to new legislation being approved by the Upper House of Japan's Parliament in November, Japan's so-called "drug lag," specifically with respect to regenerative medicine, will likely become a thing of the past. By retooling the framework of the regulatory process for regenerative medicine products, the nation has shifted from a global drug development laggard to one of the most proactive countries on the planet aiming to safely expedite growth in the burgeoning, yet volatile, stem cell industry to meet the needs of a rapidly expanding aging population. The new laws are designed to promote innovation and could provide a clear channel to rapid commercialization that will benefit industry-leading companies like Cellular Dynamics International, Inc. (NASDAQ: ICEL), Athersys, Inc. (NASDAQ: ATHX) and Cytori Therapeutics, Inc. (NASDAQ: CYTX).
Athersys Prices Registered Direct Offering of Common Stock and Warrants
GlobeNewswire - Fri Jan 10, 8:31AM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that it has entered into definitive agreements to sell 5,000,000 shares of common stock and warrants to purchase up to 1,500,000 shares of common stock, in an offering with gross proceeds of approximately $20.5 million. All of the participants in the offering are current shareholders of the company. The warrants are immediately exercisable. The warrants have an exercise price of $4.50 per share of common stock and expire on July 15, 2016. Each share of common stock, along with a warrant to purchase up to 0.30 shares of common stock, was offered for a purchase price of $4.10.
Why Athersys Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 09, 12:59PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Athersys , a clinical-stage biotechnology...
Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better
at The Street - Thu Jan 09, 10:13AM CST
The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech...
Marijuana Holdings Company Pursues Licensing for Medical and Recreational Marijuana Opportunities in Target U.S. Markets
PR Newswire - Thu Jan 09, 8:05AM CST
Marijuana Stocks are rapidly catching the attention of Wall Street as the restrictions loosen for the Cannabis industry Nationwide. Market news updates specific for marijuana sector: Alternative Fuels Americas, Inc. (OTCQB: AFAI), Growlife, Inc. (OTC: PHOT), Cannabis Sciences (OTC: CBIS), Visa Inc. (NYSE: V) and Mastercard Inc. (NSYE: MA)
Athersys, Inc. CEO Gil Van Bokkelen to Be Interviewed on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Thu Jan 09, 6:05AM CST
Athersys, Inc. (NASDAQ: ATHX) Chairman & CEO Gil Van Bokkelen will be interviewed live today by Michal Yorba on Clear Channel Business Talk Radio's The Traders Network. The interview will air today Thursday, January 9, 2014, at 2:00pm CST / 12:00pm PST / 3:00pm EST.
Athersys Announces New Patents in Japan for Stem Cell and Regenerative Medicine Technology
GlobeNewswire - Thu Jan 09, 6:00AM CST
Athersys, Inc. (Nasdaq:ATHX) today announced that it has been granted patents from the Japan Patent Office for several inventions involving its proprietary cell therapy technology. Patent No. 5398941 covers non-embryonic, multipotent stem cells, such as MultiStem, and applies to all therapeutic applications. Patent No. 5399709 covers the use of such stem cell therapies for the treatment of immune dysfunctions, such as graft-versus-host disease (GvHD), and inflammatory diseases and autoimmune disorders (e.g., inflammatory bowel disease (IBD)). And, the third patent covers the treatment of brain injuries, such as stroke and traumatic brain injury, with such multipotent stem cells.
Athersys Attains 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 10:06AM CST
Shares of Athersys reached a 52-week high of $3.20 during the first half of the trading session on Jan 6, 2014.
GTX Inc. (GTXI) Worth Watching: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 8:46AM CST
GTX Inc. was a big mover last session, with shares rising over 7%.
Athersys (ATHX) in Focus: Stock Moves 6.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 8:04AM CST
Athersys, Inc. was a big mover last session, as the company saw its shares rise by over 6% on the day.
Stock to Watch: Athersys Up 10.1% (ATHX)
Comtex SmarTrend(R) - Mon Jan 06, 10:12AM CST
Athersys (NASDAQ:ATHX) is one of today's best performing low-priced stocks, up 10.1% to $3.16 on 1.6x average daily volume. Thus far today, Athersys has traded 2.3 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (10.1% to the Dow's -0.1%) and outperformed the S&P 500 (10.1% to the S&P's -0.2%) during today's trading.
Athersys (ATHX) Shares Hit Two-Year High
at The Street - Mon Jan 06, 10:12AM CST
Athersys (ATHX) continues its month-long positive trend Monday morning and hits a two-year high.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Athersys to Present at Regen Med Investor Day March 26th in New York
GlobeNewswire - Fri Mar 07, 12:15PM CST
Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys, Inc. (Nasdaq:ATHX), will present at the second annual Regen Med Investor Day on Wednesday, March 26, 2014 at 1:30 pm (Eastern Time). The conference will be held at the Metropolitan Club in New York City.
Japan's Bold Initiative in Regenerative Medicine and Who the Big Winners Might Be
ACCESSWIRE - Mon Mar 03, 9:55AM CST
Like many other regions in the world, Japan is facing a demographic problem that threatens to pose enormous challenges for their national healthcare system in the years ahead, as the elderly segment of the population expands dramatically. According to analysis by the Ministry of Health Labor and Welfare (MHLW) in Japan, the percentage of the population that is over the age of 65 is expected to nearly double in the coming years. Given that the aging segment of the population requires greater healthcare resources and that this shift will place substantial pressure on the national healthcare system in Japan, it is understandable that the trend has received considerable attention from policy makers.
Athersys to Host Fourth Quarter and Annual Financial Results Call
GlobeNewswire - Tue Feb 25, 9:24AM CST
Athersys, Inc. (Nasdaq:ATHX) will release its 2013 fourth quarter and annual financial results at approximately 4:00 PM EST on Thursday, March 13, 2014, and host a conference call shortly thereafter at 4:30 PM EST to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
Akpabio - No Apology for Supporting Jonathan [interview]
All Africa Global Media - Thu Feb 13, 4:36AM CST
The Akwa Ibom State Governor, Godswill Akpabio, after paying a courtesy call on the National Chairman of the Peoples Democratic Party, Adamu Mu'azu, pledged his support to the new authority. Chuks Okocha presents excerpts of the session
Athersys to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 9:00AM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that the Company will present at the 2014 BIO CEO & Investor Conference to be held at the Waldorf Astoria from February 10-11, 2014 in New York City.
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013 Report
M2 - Mon Feb 03, 2:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/f28drr/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013" report to their offering. 'Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). Scope - A snapshot of the global therapeutic scenario for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). - A review of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Athersys, Inc. OPKO Health, Inc. Amicus Therapeutics, Inc. ReGenX Biosciences, LLC ArmaGen Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/f2...saccharido About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Companies Aligned to Capitalize on New Japanese Regenerative Medicine Initiatives
ACCESSWIRE - Mon Jan 13, 9:09AM CST
Thanks to new legislation being approved by the Upper House of Japan's Parliament in November, Japan's so-called "drug lag," specifically with respect to regenerative medicine, will likely become a thing of the past. By retooling the framework of the regulatory process for regenerative medicine products, the nation has shifted from a global drug development laggard to one of the most proactive countries on the planet aiming to safely expedite growth in the burgeoning, yet volatile, stem cell industry to meet the needs of a rapidly expanding aging population. The new laws are designed to promote innovation and could provide a clear channel to rapid commercialization that will benefit industry-leading companies like Cellular Dynamics International, Inc. (NASDAQ: ICEL), Athersys, Inc. (NASDAQ: ATHX) and Cytori Therapeutics, Inc. (NASDAQ: CYTX).
Athersys Prices Registered Direct Offering of Common Stock and Warrants
GlobeNewswire - Fri Jan 10, 8:31AM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that it has entered into definitive agreements to sell 5,000,000 shares of common stock and warrants to purchase up to 1,500,000 shares of common stock, in an offering with gross proceeds of approximately $20.5 million. All of the participants in the offering are current shareholders of the company. The warrants are immediately exercisable. The warrants have an exercise price of $4.50 per share of common stock and expire on July 15, 2016. Each share of common stock, along with a warrant to purchase up to 0.30 shares of common stock, was offered for a purchase price of $4.10.
Why Athersys Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 09, 12:59PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Athersys , a clinical-stage biotechnology...
Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better
at The Street - Thu Jan 09, 10:13AM CST
The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech...
Marijuana Holdings Company Pursues Licensing for Medical and Recreational Marijuana Opportunities in Target U.S. Markets
PR Newswire - Thu Jan 09, 8:05AM CST
Marijuana Stocks are rapidly catching the attention of Wall Street as the restrictions loosen for the Cannabis industry Nationwide. Market news updates specific for marijuana sector: Alternative Fuels Americas, Inc. (OTCQB: AFAI), Growlife, Inc. (OTC: PHOT), Cannabis Sciences (OTC: CBIS), Visa Inc. (NYSE: V) and Mastercard Inc. (NSYE: MA)
Athersys, Inc. CEO Gil Van Bokkelen to Be Interviewed on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Thu Jan 09, 6:05AM CST
Athersys, Inc. (NASDAQ: ATHX) Chairman & CEO Gil Van Bokkelen will be interviewed live today by Michal Yorba on Clear Channel Business Talk Radio's The Traders Network. The interview will air today Thursday, January 9, 2014, at 2:00pm CST / 12:00pm PST / 3:00pm EST.
Athersys Announces New Patents in Japan for Stem Cell and Regenerative Medicine Technology
GlobeNewswire - Thu Jan 09, 6:00AM CST
Athersys, Inc. (Nasdaq:ATHX) today announced that it has been granted patents from the Japan Patent Office for several inventions involving its proprietary cell therapy technology. Patent No. 5398941 covers non-embryonic, multipotent stem cells, such as MultiStem, and applies to all therapeutic applications. Patent No. 5399709 covers the use of such stem cell therapies for the treatment of immune dysfunctions, such as graft-versus-host disease (GvHD), and inflammatory diseases and autoimmune disorders (e.g., inflammatory bowel disease (IBD)). And, the third patent covers the treatment of brain injuries, such as stroke and traumatic brain injury, with such multipotent stem cells.
Athersys Attains 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 10:06AM CST
Shares of Athersys reached a 52-week high of $3.20 during the first half of the trading session on Jan 6, 2014.
GTX Inc. (GTXI) Worth Watching: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 8:46AM CST
GTX Inc. was a big mover last session, with shares rising over 7%.
Athersys (ATHX) in Focus: Stock Moves 6.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 8:04AM CST
Athersys, Inc. was a big mover last session, as the company saw its shares rise by over 6% on the day.
Stock to Watch: Athersys Up 10.1% (ATHX)
Comtex SmarTrend(R) - Mon Jan 06, 10:12AM CST
Athersys (NASDAQ:ATHX) is one of today's best performing low-priced stocks, up 10.1% to $3.16 on 1.6x average daily volume. Thus far today, Athersys has traded 2.3 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (10.1% to the Dow's -0.1%) and outperformed the S&P 500 (10.1% to the S&P's -0.2%) during today's trading.
Athersys (ATHX) Shares Hit Two-Year High
at The Street - Mon Jan 06, 10:12AM CST
Athersys (ATHX) continues its month-long positive trend Monday morning and hits a two-year high.
(0)
(0)Athersys Inc. (ATHXQ) Stock Research Links
Scroll down for more posts ▼